Serina Therapeutics, Inc. (SER) - Long-Term Debt to Capital

The prospects for Serina Therapeutics, Inc. (SER) depend on clinical trial outcomes and the rate of capital expenditure. The share of long-term loans within the capital structure reflects borrowing dynamics, where the 0.17 mark indicates the level of debt load. The biopharmaceutical company is developing injections for Parkinson's disease via the POZ system. The business's stability is supported by its own laboratories in the US, which develop polymer drug delivery methods.

A conservative approach requires strict control of debt load when evaluating biopharmaceutical startups. This metric is calculated as the ratio of liabilities with a maturity of more than one year to the current market capitalization. By analyzing the long-term capital structure indicator, an investor determines the business's degree of dependence on borrowed funds. For Serina Therapeutics, Inc. (SER), this is critical when funding R&D and seeking licensing partners. Low debt dependence confirms the company's resilience during a merger freeze.